Practical guide for prescribing MAOIs: debunking myths and removing barriers

@article{Grady2012PracticalGF,
  title={Practical guide for prescribing MAOIs: debunking myths and removing barriers},
  author={Meghan M. Grady and Stephen M Stahl},
  journal={CNS Spectrums},
  year={2012},
  volume={17},
  pages={2 - 10}
}
Despite the fact that monoamine oxidase inhibitors (MAOIs) can be highly effective therapeutic agents for depression and some anxiety disorders, they tend to be underutilized in clinical practice. This is due at least in part to the fact that there is a great deal of misinformation and mythology about their dietary and drug interactions. This article is intended to serve as a guide for clinicians who are not particularly familiar with MAO inhibitors; its aim is to help these clinicians… 
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
TLDR
The differing levels of evidence that support the use of ADT based on Food and Drug Administration approvals, data from randomized controlled trials or meta-analyses are discussed and theoretical pharmacodynamic principles to justify antidepressant choice in the treatment of MDD patients are discussed.
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major
“Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
TLDR
An editorial to address the discrepancy between the published literature and the view of experienced practitioners contrasted with the reality of the near-total lack of use of MAOIs, and to encourage doctors to consider these drugs earlier in the illness-course of patients, to illuminate issues that are perceived as major hurdles.
Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment‐Resistant Depression
TLDR
It is suggested that when used under close supervision and under the care of an experienced clinician in psychiatry, combination therapy may be a consideration for the management of TRD in patients not responding to monotherapy or other combinations of antidepressants.
Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
TLDR
Recent progress in RIMAs toward the treatment of treatment-resistant depression is discussed, with the new class of reversible monoamine oxidase inhibitors (RIMAs) having shown efficacy in depression, with safety and tolerability comparable to SSRIs.
The Therapeutic Potentials of Ayahuasca in the Treatment of Depression
Major depressive disorder (MDD) is generally classified as a mood disorder with a profound effect on the individual’s behavior and quality of life. According to the World Health Organization, in
A critical appraisal of the selegiline transdermal system for major depressive disorder
TLDR
Overall, STS appears to be an effective agent for major depressive disorder when held to regulatory standards and post marketing analyses.
Major Depressive Disorder : Understanding the Signi fi cance of Residual Symptoms and Balancing Ef fi cacy with Tolerability
INTRODUCTION: Major depressive disorder is a complex and frequent psychiatric condition that poses significant challenges to both the patients who experience it and the physicians who treat them. The
Ketamine as Antidepressant? Current State and Future Perspectives
TLDR
Ketamine’s powerful antidepressant effects are discussed, and NMDAR antagonists provide an entirely new way of treating the manifold appearances of depression that should not be left unused.
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability.
TLDR
Linking symptoms with malfunctioning brain circuits and neurotransmitters provides a targeted approach for achieving sustained remission, and neurobiology provides a rational basis for individualizing treatment of patients with major depression.
...
1
2
3
4
...

References

SHOWING 1-10 OF 55 REFERENCES
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art.
  • M. Rapaport
  • Medicine
    The Journal of clinical psychiatry
  • 2007
TLDR
MAOIs have been well established as an effective intervention for people with treatment-resistant depression, and transdermal formulations may provide a valuable therapeutic option and eliminate the drug-food interaction.
A clinical overview of monoamine oxidase inhibitors.
  • S. Zisook
  • Psychology, Medicine
    Psychosomatics
  • 1985
TLDR
The major role of MAOIs now appears to be in depressed patients refractory to other pharmacologic treatments, and especially in outpatients with features of both anxiety and depression.
Revisiting monoamine oxidase inhibitors.
  • K. Krishnan
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2007
TLDR
The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.
MAO inhibitors: Risks, benefits, and lore
TLDR
The use, risks, and benefits in clinical medicine of monoamine oxidase inhibitors, the first antidepressants introduced, are discussed.
Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
TLDR
A case series demonstrating the safety and efficacy of adding a stimulant to an MAOI or to a combination of TCA andMAOI in the treatment of intractable depression is reported.
Dietary consideration in MAO inhibitor regimens.
TLDR
This paper proposes a reasonable MAOI diet, in common food terms, with a rationale supported by a critical review of the literature, and principles for dietary counseling of patients receiving MAOIs are listed and suggestions for achieving dietary adherence are made.
Translating the evidence on atypical depression into clinical practice.
TLDR
A newer MAOI, the transdermal formulation of selegiline, may provide all of the efficacy of the older MAOIs in treating atypical depression without causing as great of adverse events and no diet restrictions.
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication.
  • S. Feinberg
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2004
TLDR
Another possible indication for this therapeutic regimen is treatment of attention-deficit/hyperactivity disorder in an adult patient whose major depression had uniquely responded to the MAOI tranylcypromine.
Safety and tolerability of antidepressants: weighing the impact on treatment decisions.
  • A. Schatzberg
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2007
TLDR
Research continues to elucidate new agents that may combine efficacy with a minimum of side effects, as well as new methods of predicting individual response to particular antidepressants.
CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
TLDR
With properly motivated and complaint patients and careful clinical monitoring by the prescribing psychiatrist, stimulant potentiation of MAOIs may be a viable option for treatment-resistant depressed patients.
...
1
2
3
4
5
...